CXCL13 has been observed to be expressed in the meninges of the CNS during autoimmune diseases and has emerged as a candidate as a therapeutic target for multiple sclerosis (MS) [27, 55–57] due to its role in myelinating glial cells [58]. The gene discussed is CXCL13; the disease is myeloid sarcoma.